Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
Subjects will receive a total of two doses administered IM on Days 0 and 56. Subjects will be monitored for approximately 421 days (one year following the last study injection), including safety laboratory analyses done just prior to and 7 days following each study injection. Tears and nasal swabs will be obtained for exploratory antibody analysis at Days 0, 70, and 224. Blood samples will be obtained for immunological assays (secondary and exploratory) at Days 0, 7, 14, 56, 63, 70, 84, and 224).
Epistemonikos ID: faaa7bde18d5349b0baef1854750cbf368e3f3cd
First added on: May 21, 2024